HDAC-IN-46

• Description :

  HDAC-IN-46 (compound 12c) is a potent HDAC inhibitor with an IC50 value of 0.21 μM and 0.021 μM for HDAC1 and HDAC6, respectively. HDAC-IN-46 upregulates p-p38, and downregulates Bcl-xL and cyclin D1 in MDA-MB-231 cells. HDAC-IN-46 induces significant G2 phase arrest and apoptosis. HDAC-IN-46 can be used for researching triple-negative breast cancer (TNBC) [1].

• UNSPSC :

  12352005

• Target :

  Apoptosis; HDAC

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage; Epigenetics

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/hdac-in-46.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(NO)CCCCCCCN1N=NC(C2=CC=C(C3=C(CC)N=C(N)N=C3N)C=C2)=C1

• Molecular Formula :

  C22H30N8O2

• Molecular Weight :

  438.53

• References & Citations :

  [1]Wu B, et al. Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity. Bioorg Med Chem. 2020 Mar 15;28 (6) :115345.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  HDAC1; HDAC6

• CAS Number :

  [2562386-85-8]